Microbot Medical®’s LIBERTY® Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial Sites

Microbot Medical reported commercial adoption of its LIBERTY Endovascular Robotic System by multiple accounts, including two sites from the pivotal ACCESS-PVI clinical trial, marking early progress in its full market release. The company is leveraging updated medical guidelines regarding radiation and ergonomics and recently appointed Alon Tamir as VP of Sales, EMEA to support international commercialization efforts.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.